Baxter International Inc.(BAX)Earnings, Financials & Key RatiosBaxter International Inc. (BAX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
which warrants caution until operational stability is clearly demonstrated.
Baxter International Inc. (BAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Baxter International Inc. (BAX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.36vs $0.31+15.8% | $2.7Bvs $2.6B+3.3% |
| Q1 2026 | Feb 12, 2026 | $0.44vs $0.53-17.0% | $3.0Bvs $2.8B+5.3% |
| Q4 2025 | Oct 30, 2025 | $0.69vs $0.60+15.0% | $2.8Bvs $2.8B+0.4% |
| Q3 2025 | Jul 31, 2025 | $0.59vs $0.60-1.7% | $2.8Bvs $2.9B-2.3% |
Recent stock market news and headlines for Baxter International Inc. (BAX)
Baxter International Inc. (NYSE: BAX), a global medtech leader, today published its newly renamed [url="]2025 Sustainability Report[/url], highlighting the comp
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.
Key metrics vs top competitors for Baxter International Inc. (BAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.86 | $11.8B | -13.06 | 5.72% | -8.51% | -14.58% | 2.97% | |
| $156.30 | $56.63B | 26.81 | 8.23% | 5.33% | 4.54% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — | |
| $94.82 | $54.6B | 51.81 | 11.55% | 17.34% | 10.54% | — | |
| $5.07 | $198.66M | -0.87 | 814.07% | -828.62% | -146.29% | — | |
| $86.84 | $9.89B | 26.56 | 4.03% | 2.95% | 8.14% | — |
Baxter International Inc. (BAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Baxter International Inc. (BAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Mar 19, 2026·SEC
Mar 16, 2026·SEC
Get notified when BAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Baxter International Inc. (BAX) stock FAQ — growth, dividends, profitability & financials explained
Baxter International Inc. (BAX) reported $11.32B in revenue for fiscal year 2025. This represents a 108% increase from $5.44B in 1996.
Baxter International Inc. (BAX) grew revenue by 5.7% over the past year. This is steady growth.
Baxter International Inc. (BAX) reported a net loss of $1.10B for fiscal year 2025.
Yes, Baxter International Inc. (BAX) pays a dividend with a yield of 2.97%. This makes it attractive for income-focused investors.
Baxter International Inc. (BAX) has a return on equity (ROE) of -14.6%. Negative ROE indicates the company is unprofitable.
Baxter International Inc. (BAX) generated $501.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
